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PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to 
address in a systematic review protocol*  
Section and topic Item 
No 
Checklist item   
ADMINISTRATIVE INFORMATION   
Title:     
 Identification 1a Identify the report as a protocol of a systematic review  P1 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such - - 
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number  P2 
Authors:     
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of 
corresponding author 
 P1 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review  P14 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list 
changes; otherwise, state plan for documenting important protocol amendments 
- - 
Support:     
 Sources 5a Indicate sources of financial or other support for the review  P15 
 Sponsor 5b Provide name for the review funder and/or sponsor  P15 
 Role of 
sponsor or 
funder 
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol  P15 
INTRODUCTION   
Rationale 6 Describe the rationale for the review in the context of what is already known  P4/5 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, 
comparators, and outcomes (PICO) 
 P5 
METHODS   
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as 
years considered, language, publication status) to be used as criteria for eligibility for the review 
 P6/7 
Information 
sources 
9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other 
grey literature sources) with planned dates of coverage 
 P7/8 
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could 
be repeated 
 P8 
Study records:     
 Data 
management 
11a Describe the mechanism(s) that will be used to manage records and data throughout the review  P8 
 Selection 
process 
11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the 
review (that is, screening, eligibility and inclusion in meta-analysis) 
 P8/9 
 Data 
collection 
process 
11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any 
processes for obtaining and confirming data from investigators 
 P9 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data 
assumptions and simplifications 
 P9/10 
Outcomes and 
prioritization 
13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with 
rationale 
 P10 
Risk of bias in 
individual studies 
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the 
outcome or study level, or both; state how this information will be used in data synthesis 
 P11 
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised  P11/12 
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and 
methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall’s τ) 
 P11/12 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)  P11/12 
15d If quantitative synthesis is not appropriate, describe the type of summary planned  P11/12 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within 
studies) 
 P11/12 
Confidence in 
cumulative 
evidence 
17 Describe how the strength of the body of evidence will be assessed (such as GRADE)  P12/13 
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important 
clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the 
PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.  
 
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and 
meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647. 
 
